ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

Medidata Wins Inaugural SCOPE Site Innovation Award for Pioneering Advancements in Site Experience with Leading-Edge Technology

Medidata Rave Companion, the industry’s first data entry companion, is recognized for improving the speed and accuracy of information capture and quality

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, was presented with the inaugural Site Innovation Award for its groundbreaking work in improving efficiency in clinical trials by the Summit for Clinical Ops Executives (SCOPE).

Medidata Rave Companion was selected as the winner for its ability to elevate the site experience, enabling sites to spend more time conducting research, caring for patients, and delivering high-quality data to sponsors. This next-generation solution enhances data quality and lowers monitoring costs by making it easier and faster to input information into Medidata Rave EDC from other electronic systems, including electronic health records (EHR). In fact, one clinical trial site reported that data entry was 44 times faster with Rave Companion than doing it manually.

“We’re honored to receive the Site Innovation Award and to be recognized by SCOPE,” said Dan Braga, vice president, electronic health record and healthcare solutions, Medidata. “We are inspired to continue innovating in all aspects of clinical trials to enhance the experience for everyone involved, including patients.”

“Data entry within a clinical trial is often time-consuming and is an area that can affect a site’s overall quality of work,” said Melanie Curole, senior research coordinator, Velocity Clinical Research, a Medidata Customer. “Rave Companion is user-friendly, lessens the amount of time spent on data entry, and decreases the opportunity for transcription errors - helping to ensure high-quality data is being delivered to sponsors while meeting their timelines.”

SCOPE is a leading global conference series that focuses on advances and innovative solutions in all aspects of clinical trial research, planning, management, operations, and investments.

About Medidata

Medidata is powering smarter treatments and healthier people through digital solutions to support clinical trials. Celebrating 25 years of ground-breaking technological innovation across more than 33,000 trials and 10 million patients, Medidata offers industry-leading expertise, analytics-powered insights, and the largest patient-level historical clinical trial data set in the world. More than 1 million registered users across 2,200+ customers trust Medidata’s seamless, end-to-end platform to improve patient experiences, accelerate clinical breakthroughs, and bring therapies to market faster. The company is a wholly owned subsidiary of Dassault Systèmes (Euronext Paris: FR0014003TT8, DSY.PA), which with its 3DEXPERIENCE platform is positioned to lead the digital transformation of life sciences in the age of personalized medicine with the first end-to-end scientific and business platform, from research to commercialization. Medidata is headquartered in New York City and has been recognized as a Leader by Everest Group and IDC. Discover more at www.medidata.com and follow us @Medidata.

About Dassault Systèmes

Dassault Systèmes, the 3DEXPERIENCE® Company, is a catalyst for human progress. We provide business and people with collaborative virtual environments to imagine sustainable innovations. By creating virtual twin experiences of the real world with our 3DEXPERIENCE platform and applications, our customers can redefine the creation, production and life-cycle-management processes of their offer and thus have a meaningful impact to make the world more sustainable. The beauty of the Experience Economy is that it is a human-centered economy for the benefit of all –consumers, patients, and citizens. Dassault Systèmes brings value to more than 300,000 customers of all sizes, in all industries, in more than 150 countries. For more information, visit www.3ds.com

© Dassault Systèmes. All rights reserved. 3DEXPERIENCE, the 3DS logo, the Compass icon, IFWE, 3DEXCITE, 3DVIA, BIOVIA, CATIA, CENTRIC PLM, DELMIA, ENOVIA, GEOVIA, MEDIDATA, NETVIBES, OUTSCALE, SIMULIA and SOLIDWORKS are commercial trademarks or registered trademarks of Dassault Systèmes, a European company (Societas Europaea) incorporated under French law, and registered with the Versailles trade and companies registry under number 322 306 440, or its subsidiaries in the United States and/or other countries.

Contacts

Recent Quotes

View More
Symbol Price Change (%)
AMZN  244.22
+21.36 (9.58%)
AAPL  270.37
-1.03 (-0.38%)
AMD  256.12
+1.28 (0.50%)
BAC  53.45
+0.42 (0.79%)
GOOG  281.82
-0.08 (-0.03%)
META  648.35
-18.12 (-2.72%)
MSFT  517.81
-7.95 (-1.51%)
NVDA  202.49
-0.40 (-0.20%)
ORCL  262.61
+5.72 (2.23%)
TSLA  456.56
+16.46 (3.74%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.